Category Press Releases

Parabilis Medicines and Regeneron Pharmaceuticals Partner to Develop Novel Antibody-Helicon™ Conjugates

Parabilis Medicines Partners With Regeneron Pharmaceuticals to Develop Antibody-Helicon™ Conjugates Across Multiple Diseases Parabilis Medicines has entered into a major strategic research collaboration with Regeneron Pharmaceuticals aimed at advancing a new generation of targeted medicines designed to tackle some of…

Read MoreParabilis Medicines and Regeneron Pharmaceuticals Partner to Develop Novel Antibody-Helicon™ Conjugates

Genentech Wins FDA Approval for Tecentriq in ctDNA-Guided Adjuvant Treatment of Muscle-Invasive Bladder Cancer

Genentech Receives FDA Approval for Tecentriq in ctDNA-Guided Treatment of Muscle-Invasive Bladder Cancer Genentech announced that the U.S. Food and Drug Administration has approved both Tecentriq and Tecentriq Hybreza as adjuvant treatments for adult patients with muscle-invasive bladder cancer (MIBC)…

Read MoreGenentech Wins FDA Approval for Tecentriq in ctDNA-Guided Adjuvant Treatment of Muscle-Invasive Bladder Cancer

ICUS Applauds New Proposal Advancing CEUS Training for Sonographers

ICUS Supports New Sonography Training Standards Expanding Education in Contrast Enhanced Ultrasound International Contrast Ultrasound Society has expressed strong support for newly proposed accreditation standards that could significantly expand education and training in contrast enhanced ultrasound (CEUS) for future sonographers…

Read MoreICUS Applauds New Proposal Advancing CEUS Training for Sonographers

Next Health Opens New Peoria Location Offering Advanced Longevity and Preventive Care Services in Arizona

Next Health Opens New Peoria Location Offering Advanced Longevity and Preventive Care Services in Arizona Next Health, a provider of preventive wellness, longevity, and personalized health optimization services, has announced the grand opening of its newest location in Peoria, Arizona.…

Read MoreNext Health Opens New Peoria Location Offering Advanced Longevity and Preventive Care Services in Arizona

Medisca and dsm–firmenich Collaborate to Broaden U.S. Access to Pharmaceutical-Grade Vitamin APIs

Medisca and dsm–firmenich Collaborate to Broaden U.S. Access to Pharmaceutical-Grade Vitamin APIs for Compounding Pharmacies Medisca, a global provider of personalized pharmaceutical solutions and compounding technologies, has announced a strategic partnership with dsm–firmenich, an international manufacturer of pharmaceutical ingredients and…

Read MoreMedisca and dsm–firmenich Collaborate to Broaden U.S. Access to Pharmaceutical-Grade Vitamin APIs

Vetter Begins Construction of New Manufacturing Facility in Germany

Vetter Begins Building New Manufacturing Facility in Germany Vetter, a globally recognized Contract Development and Manufacturing Organization specializing in aseptic filling and pharmaceutical manufacturing services, has officially launched construction activities for its newest production facility in Saarlouis, Germany. The milestone…

Read MoreVetter Begins Construction of New Manufacturing Facility in Germany

Johnson & Johnson Launches Generation Fine Campaign Focused on Depression Remission

Johnson & Johnson Launches “Generation Fine” Campaign to Encourage Better Conversations Around Depression Care and Remission Johnson & Johnson has launched Generation Fine, a new global awareness campaign focused on reshaping conversations around depression treatment and encouraging people living with…

Read MoreJohnson & Johnson Launches Generation Fine Campaign Focused on Depression Remission

Rapid Medical’s TIGERTRIEVER 13 Shows Encouraging 90-Day Results in DISTALS Trial, Supporting Key Safety and Efficacy Data

Rapid Medical Reports Positive DISTALS Trial Results for TIGERTRIEVER 13 in Distal Stroke Treatment Rapid Medical, a medical technology company focused on advanced stroke treatment solutions, has announced full results from the DISTALS randomized clinical trial during the 11th European…

Read MoreRapid Medical’s TIGERTRIEVER 13 Shows Encouraging 90-Day Results in DISTALS Trial, Supporting Key Safety and Efficacy Data

Viridian Therapeutics Plans Concurrent Offerings of Notes, Common Stock, and Preferred Shares

Viridian Therapeutics Plans Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Shares, and Series B Non-Voting Convertible Preferred Stock Viridian Therapeutics (Nasdaq: VRDN), a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and rare diseases, has…

Read MoreViridian Therapeutics Plans Concurrent Offerings of Notes, Common Stock, and Preferred Shares